Friday, March 02, 2018 12:41:06 PM
- $36.88M or $13.69/sh equity, including
- $26.58M or $10.07/sh deposit value, having $16.03M or $6.07/sh refundable
Stock is traded far below these liquid assets with a discount > 45% now and
stock is traded far below equity with a discount > 75% now.
No company likes to raise money via an offering below this NAV value, especially not the hard liquid asset value.
It is our assumption that - if needed for production - will either take off some money from the refundable deposits or will receive a proper loan with less than 10% interest rate.
As mentioned earlier, the closing of the acquisition of the Health Product Manufacturer, which is about to finalize, may also boost the company's balance sheet bringing these now non-refundable deposits back to work.
Further more, company has received the GMP certification and will start production in 2Q18.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM